---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-009050"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:46:10.523695+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M

## Summary
- 2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.
- Company notified trustee on Feb 23, 2023; no Net Sales Payment due per CVR terms.
- CVR relates to Celgene acquisition from Nov 2019; future payments may be disclosed on BMS website.

## SEC filing metadata
- accession: 0001140361-23-009050
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/0001140361-23-009050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000114036123009050/brhc10048710_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-009050
- JSON: https://secwatch.observer/filing/0001140361-23-009050.json
- Plain text: https://secwatch.observer/filing/0001140361-23-009050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.